Regulation of von Willebrand factor (VWF)
AssigneeBand Therapeutics, LLC
InventorsShuhao Zhu, James C. Gilbert
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to agents, compositions targeting to von Willebrand factor (VWF). The VWF targeting agents are synthetic polynucleotides, including VWF binding agents and their reversal agents. The VWF binding agents are VWF binding aptamers that bind to and inhibit the VWF activities. The VWF binding agents can be reversed using reversal agents to reverse the inhibitory effect and thereby restore VWF activities. The disclosure further provides methods for regulating the activities of VWF, thereby modulating VWF mediated platelet functionality, such as thrombosis, the present VWF targeting agents may be used for preventing thrombus formation and treating thrombotic disorders.
Claims15
A method for treating a clinical condition associated with elevated levels of plasma VWF in a patient comprising:
- administrating to the patient a VWF binding aptamer comprising the nucleic acid sequence presented by SEQ ID No:
- 3;
- and reversing the effect of the VWF binding aptamer using a reversal agent comprising the nucleic acid sequence presented by SEQ ID No:
- 9, wherein the reversal agent is administered at a ratio of 1:1 relative to the VWF binding aptamer or less in moles when the levels of plasma VWF need to be increased in the patient receiving the treatment of the VWF binding aptamer.
A method of modulating VWF activity in a subject comprising administering to the circulatory system of the subject a VWF binding aptamer having the nucleic acid sequence presented by SEQ ID NO:
- 3, and reversing the effect of the VWF binding aptamer using a reversal agent having the nucleic acid sequence presented by SEQ ID NO:
- 9 wherein the reversal agent is used at a ratio of 1:1 to the VWF binding aptamer or less in moles when the activity of plasma VWF needs to be increased.
Dependencies are inferred from the claim text.